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Abstract
Background: Tuberculosis infection, disease and mortality are all less common at high than low altitude and ascent
to high altitude was historically recommended for treatment. The immunological and mycobacterial mechanisms
underlying the association between altitude and tuberculosis are unclear. We studied the effects of altitude on
mycobacteria and antimycobacterial immunity.
Methods: Antimycobacterial immunity was assayed in 15 healthy adults residing at low altitude before and after they
ascended to 3400 meters; and in 47 long-term high-altitude residents. Antimycobacterial immunity was assessed as
the extent to which participants’ whole blood supported or restricted growth of genetically modified luminescent
Bacille Calmette-Guérin (BCG) mycobacteria during 96 hours incubation. We developed a simplified whole blood
assay that could be used by a technician in a low-technology setting. We used this to compare mycobacterial growth
in participants’ whole blood versus positive-control culture broth and versus negative-control plasma.
Results: Measurements of mycobacterial luminescence predicted the number of mycobacterial colonies cultured six
weeks later. At low altitude, mycobacteria grew in blood at similar rates to positive-control culture broth whereas
ascent to high altitude was associated with restriction (p≤0.002) of mycobacterial growth to be 4-times less than in
culture broth. At low altitude, mycobacteria grew in blood 25-times more than negative-control plasma whereas
ascent to high altitude was associated with restriction (p≤0.01) of mycobacterial growth to be only 6-times more than
in plasma. There was no evidence of differences in antimycobacterial immunity at high altitude between people who
had recently ascended to high altitude versus long-term high-altitude residents.
Conclusions: An assay of luminescent mycobacterial growth in whole blood was adapted and found to be feasible in
low-resource settings. This demonstrated that ascent to or residence at high altitude was associated with decreased
mycobacterial growth in whole blood relative to controls, consistent with altitude-related augmentation of
antimycobacterial cellular immunity.
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Introduction
One third of the world’s population is estimated to be latently
infected with tuberculosis (TB) and progression to TB disease
causes 1.4 million deaths each year [1]. However, in the great
majority of immunocompetent people latently infected with TB,
antimycobacterial immunity prevents progression to
symptomatic disease [1]. Furthermore, in the pre-antibiotic era
many episodes of symptomatic TB disease were controlled by
the host immune system and apparently resolved
spontaneously [2]. Even with effective antibiotic treatment, the
likelihood of treatment achieving a lasting cure is also
influenced by host immunity [3,4]. Thus, TB infection
represents a balance between progression of the
mycobacterial infection and containment by antimycobacterial
immunity. Antibiotic-resistant TB has increasing prevalence but
limited diagnosis and treatment facilities and the emergence of
TB strains resistant to almost all known antibiotics [5] is
renewing interest in approaches to strengthen patients’
antimycobacterial immunity [6].
Altitude therapy and TB care in mountain sanatoria have
been used historically for TB care [7] and epidemiological
studies suggest that high altitude is associated with reduced
incidence of TB infection, disease and mortality [8-17].
However, the mechanisms underlying this apparent altitude-
mediated effect are poorly understood, and are likely to include
both mycobacterial transmission and host antimycobacterial
immunity [18].
Antimycobacterial immunity has been studied in vitro by
quantifying the restriction of mycobacterial growth by immune
cells [19,20]. This has been facilitated by the development of
genetically modified luminescent mycobacteria that allow rapid
and accurate mycobacterial quantification, overcoming their
slow growth on solid media and inaccuracies caused by
mycobacteria clumping [21,22]. A whole-blood model of the
extent to which blood cells support or restrict the growth of
luminescent mycobacteria has been used effectively for
investigating aspects of human antimycobacterial cellular
immunity [23]. These include correlation with cytokine
production and tuberculin skin test status [24], evaluation of
vaccine candidates [14,25] and of nutritional augmentation of
antimycobacterial immunity [26].
To enable studies in a high altitude setting, we simplified
previously published whole-blood assays of antimycobacterial
immunity so that a technician in a low-technology setting with
only portable equipment and without a biosafety cabinet,
centrifuge or freezer could concurrently perform multiple
assays. Since the antimycobacterial immunity assays were
repeated at different times and locations, variations in
temperature, oxygen tension, mycobacterial stocks,
atmospheric pressure and other factors inevitably caused inter-
assay differences in mycobacterial growth. To reduce the effect
of these inter-assay variations in mycobacterial growth,
antimycobacterial immunity was assessed as the extent to
which participants’ whole blood supported or restricted
mycobacterial growth relative to concurrent growth in positive-
control culture broth. Humoral (acellular) immunity is relatively
inactive against mycobacteria and plasma is generally
tuberculostatic (neither supporting mycobacterial growth nor
killing mycobacteria). Thus antimycobacterial immunity was
also inferred from the extent to which whole blood supported
mycobacterial growth relative to negative-control plasma.
We used this assay to assess the effects of high altitude on
peoples’ antimycobacterial immunity.
Methods
Ethics statement
This study was approved by the Ethics Committees of the
Asociación Benéfica PRISMA (Lima), and the Universidad
Peruana Cayetano Heredia (Lima). All participants were fully
informed in their preferred language (Spanish or English) about
this study and gave signed written consent. Mechanisms were
in place to provide a free chest radiograph, sputum testing and
medical consultation to any participants with suspected TB and
to refer any participants with symptoms suggestive of TB to the
local National TB Control Program, which provides free TB
diagnosis and treatment. All data collected and questionnaires
completed were confidential and identified by means of a
coding system rather than by the subject’s name.
Subjects
The effect of altitude on antimycobacterial immunity was
studied by comparing samples collected under three conditions
(Figure 1). Firstly, low-altitude residents living in Lima, Peru,
less than 100 meters above sea level, provided an initial blood
sample at low-altitude. Secondly, they then provided another
sample after ascent to high altitude in Cusco, Peru, 3400
meters above sea level. Thirdly, samples were also obtained
from permanent residents at the same high altitude location.
Participants were identified by inviting university staff, affiliates
and students to participate. Inclusion criteria were healthy
adults who gave informed written consent for this research that
had internationally accredited ethical committee approval.
Exclusion criteria were travel to high altitude during the
previous month or having a tuberculin skin test within the
previous six months, in case these affected antimycobacterial
immunity. A questionnaire was used to characterize
demographic data, previous TB exposure and vaccination with
bacille Calmette-Guérin (BCG). The nutritional status of the
individuals was assessed by measuring mid-upper arm
circumference, height, weight and calculating body mass index.
Mycobacteria stocks
Luminescent Mycobacterium bovis BCG (Montreal strain)
were used that were a gift from collaborators who had
transformed them to constitutively express the lux gene as
described [21]. BCG was used rather than virulent
Mycobacterium tuberculosis for biosafety reasons. These
mycobacteria were maintained by continuous passage in stock
cultures in exponential growth in Middlebrook 7H9 culture broth
supplemented with 10% growth supplement (oleic acid,
albumin, dextrose and catalase, OADC, Becton Dickinson,
Oxford, UK). All culture media were also supplemented with
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hygromycin (50 µg/mL; Roche, Lewes, UK) to select the
genetically modified luminescent strain [22].
Mycobacterial quantification
Mycobacterial stock cultures were quantified each time that
they were required for experimental work and approximately
twice weekly when growth became macroscopically visible,
indicating that dilution was required to maintain exponential
growth. Quantification was done by taking an aliquot to which
substrate (1% n-decyl aldehyde in 100% ethanol, Sigma, MO,
USA) was added for immediate measurement of luminescence
in an automated portable luminometer (Turner 2020, Turner
designs, CA, USA). The base-ten logarithms (log10) of the
luminometer readings (in arbitrary relative light units) had an
approximately Gaussian distribution and are referred to
throughout this manuscript as “luminescence”. In baseline
studies, serial logarithmic dilutions of the stock broth cultures
and concurrent cultures in blood and plasma were quantified by
luminescence and then immediately plated on Middlebrook
7H11 culture agar containing OADC supplement. These were
incubated for six weeks and then the number of colonies was
counted. This confirmed that luminescence was linearly related
to the number of mycobacterial colonies cultured six weeks
later, as reported previously [24]. Thus the measurement of
luminescence determined the concentration of these
genetically modified mycobacteria in less than one minute
Figure 1.  Study design.  Fifteen low altitude residents had
blood drawn at low altitude, which was used to obtain whole
blood and plasma samples that, together with culture broth
samples, were then inoculated with luminescent mycobacteria.
In half of these samples, baseline luminescence readings were
measured straight away. The other half of these samples were
incubated at 37°C for 96 hours and luminescence readings
were repeated. The low altitude residents ascended to high
altitude and together with a group of 47 high altitude residents,
blood samples were taken and the experiment repeated.
doi: 10.1371/journal.pone.0074220.g001
instead of the weeks that are generally required for quantifying
most non-luminescent mycobacteria.
Mycobacterial inoculum
For each assay, an aliquot of the mycobacterial stocks that
were maintained in exponential growth was diluted with
phosphate-buffered saline at pH 6.8 (Sigma-Aldrich, St Louis,
MO, USA) until its luminescence indicated a mycobacterial
concentration equivalent to 740 mycobacterial colonies per 100
µL (see below). This concentration was selected so that after
dilution in whole blood for the antimycobacterial immunity
assay, the concentration of mycobacterial colony forming units
would be approximately one per 30 monocytes. The actual
multiplicity of infection depended upon the subject’s blood
monocyte concentration: approximately one colony forming unit
per 10 monocytes if the subject’s monocyte concentration was
at the lower limit of the normal range; or one colony forming
unit per 50 monocytes if the subject’s monocyte concentration
was at the upper limit of the normal range. After the pilot
experiments that determined and optimized these
concentrations, human blood monocytes were neither
quantified nor purified for the research described below. Thus
the actual cell counts at low and high altitude were not
determined.
Blood samples
At least 1.5 ml of venous blood was collected into
heparinized tubes (LH-Metal-Analytik, Sarstedt, Numbrecht,
Germany) and kept at 37°C in a portable incubator (App-Chem
Ltd, Wrexham, UK) until analysis. One ml of blood was
centrifuged to obtain plasma (the liquid part of blood with cells
removed). Volumes of 450 µL of each subject’s blood and of
their plasma were supplemented with equal volumes of diluent
(RPMI 1640 with 1% HEPES N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid; Life Technologies Ltd, Paisley, UK) to
stabilize pH and provide nutrients for blood cells (where
present) during incubation for all the procedures described
below.
Antimycobacterial immunity assays
The mycobacterial inoculum (100 µL) was mixed with 900 µL
aliquots of blood, positive-control culture broth and negative-
control plasma. One positive-control culture broth specimen
was analyzed together with each batch of approximately 10
participants’ blood/plasma samples that were analyzed
together. Mycobacterial concentrations were quantified in all
aliquots immediately after inoculation as a baseline and in
identical concurrently prepared aliquots after they had been
incubated for 96 hours at 37°C in room air. Analysis of
mycobacterial concentrations was done by addition of nine
volumes of sterile water to reduce opacity (and lyse blood cells
where present), followed by the addition of substrate for
measurement of luminescence as described above.
(a): Mycobacterial growth.  The raw data characterizing the
growth of mycobacteria in each of blood, positive-control
culture broth and negative-control plasma were calculated as
the luminescence readings after 96-hours incubation minus the
baseline pre-incubation luminescence readings.
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(b): Antimycobacterial immunity.  Antimycobacterial
immunity was assessed as the extent to which participants’
whole blood supported or restricted mycobacterial growth
relative to concurrent growth in positive-control culture broth
(growth during 96 hours incubation in culture broth minus
concurrent growth in blood). Antimycobacterial immunity was
also inferred from the extent to which whole blood supported
mycobacterial growth relative to negative-control plasma
(growth during 96 hours incubation in blood minus concurrent
growth in plasma).
Quadruplet assays
To determine the reproducibility of assay results, all the
above baseline and 96-hour measurements in blood, positive-
control culture broth and negative-control plasma were
performed using quadruplet identical tubes. Results were
analyzed using only the data from the first of the quadruplet
tubes and also using the average of the quadruplet tubes.
Data analysis and statistical methods
All statistical tests were two-tailed and used STATA version
11 software (STATA Corporation, College Station, Texas).
Fisher’s exact test was used for categorical variables. Data
were not normally distributed so non-parametric tests were
used: the Wilcoxon rank sum test for unpaired data and the
Wilcoxon signed-rank test for paired low altitude versus high
altitude comparisons in each individual.
Results
Subjects
Fifteen low-altitude residents were studied at low altitude and
again an average of 11.1 (standard deviation 6.4) hours after
ascent to high altitude. Additionally, 47 permanently high-
altitude residents were studied only at this high altitude. The
demographic and anthropometric characteristics of these
participants are shown in Table 1. The low-altitude residents
were older than the high-altitude residents (26 versus 22 years
respectively, p<0.001). There was no evidence of differences in
nutritional indicators (body mass index, upper arm
circumference), sex or rates of previous BCG vaccination (all
p≥0.4). No participants had previously been diagnosed with TB
disease.
(a): Mycobacterial growth.  The mycobacterial growth
results are shown in Table 2a. At low and high altitude,
mycobacteria grew abundantly in positive-control culture broth,
minimally in negative-control plasma and there was
intermediate mycobacterial growth in whole blood. Ascent from
low to high altitude was associated with increases in
mycobacterial growth in culture broth (p<0.001) and plasma
(p=0.004) but not in whole blood (p=0.3). High altitude
increased mycobacterial growth similarly in culture broth and in
plasma, so there was no evidence of any difference in
mycobacterial growth in culture broth relative to plasma
comparing low versus high altitude results (p≥0.2).
(b): Antimycobacterial immunity
The restriction of mycobacterial growth by whole blood
relative to positive-control culture broth is shown in Table 2b
and in Figure 2. At low altitude, mycobacteria grew similarly
abundantly in blood as in the positive-control culture broth
(p=0.4). Specifically, mycobacterial growth in blood was only
0.17 logs (i.e. 1.5-times) less than growth in positive-control
culture broth. In contrast, ascent to high altitude was
associated with restriction (p=0.002) of mycobacterial growth in
the same participants’ blood to be 0.62 logs (i.e. 4-times) less
abundant than the positive-control culture broth. Blood from
long-term high-altitude residents also restricted mycobacterial
growth to be 0.65 logs (i.e. 4-times) less abundant than the
positive-control culture broth (p=0.001 versus low altitude
residents at low altitude).
Antimycobacterial immunity was assessed in 15 low altitude
residents as they ascended to high altitude (square symbols
joined by lines) and in 47 high altitude residents at high altitude
(circular symbols). The vertical axis shows luminescence
recorded as the log10 of measured relative light units (arbitrary
units) produced by genetically modified luminescent
mycobacteria. The increase in luminescence over 96 hours
incubation is shown positive-control culture broth minus whole
blood. For low altitude residents at low altitude, mycobacteria
grew similarly in culture broth and blood. Ascent to high altitude
was associated with restriction of mycobacterial growth in
whole blood relative to culture broth, similar to the values for
high altitude residents at high altitude.
The extent to which whole blood supported mycobacterial
growth relative to negative-control plasma is also shown in
Table 2b. At low altitude, mycobacteria grew 1.4 logs (i.e. 25-
times) more abundantly in participants’ whole blood than in
their negative-control plasma. In contrast, ascent to high
altitude was associated with restriction (p=0.01) of
mycobacterial growth in the same participants’ blood to be only
Table 1. Characteristics of study participants.
Characteristic
Low altitude
residents
High altitude
residents p-value
 N=15 N=47  
Male % 47 55 1.0
[95% confidence intervals] [18,75] [41,70]  
(n/N) (7/15) (26/47)  
Age median years 26 22 <0.001
(interquartile range) (24, 31) (20, 23)  
BCG scar seen % 71 46 0.4
[95% confidence intervals] [44,98] [30,61]  
(n/N) (10/14) (20/44)  
Body mass index median kg/m2 21 21 0.6
(IQR) (19, 23) (20, 23)  
Mid upper arm circumference
(median cm) 27 26 0.7
(interquartile range) (23, 29) (25, 28)  
Abbreviations: N, group size; n, number.
doi: 10.1371/journal.pone.0074220.t001
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Table 2. Altitude effects on luminescence indicating
mycobacterial growth* in blood, positive-control culture
broth and negative-control plasma.
 Mycobacterial growth  p-values
 
Low altitude
residents at
low altitude
Low
altitude
residents
at high
altitude
High
altitude
residents
at high
altitude  
Low
altitude
residents:
change
on ascent
to high
altitude
At high
altitude:
low
altitude
residents
versus
high
altitude
residents
Low
altitude
residents
at low
altitude
versus
high
altitude
residents
at high
altitude
 (n=15) (n=15) (n=47)     
(a) MYCOBACTERIAL
GROWTH       
Culture
broth 1.1 1.9 1.5  <0.001 <0.001 <0.001
 [0.70, 1.1] [1.9,2.3]
[1.5,
1.7]     
Whole
blood 0.86 1.2 0.95  0.3 0.7 0.5
 [0.53, 1.2] [0.30,1.4]
[0.48,
1.4]     
Plasma -0.55 0.40 0.094  0.004 0.9 <0.001
 [-0.64,-0.37]
[-0.59,
0.70]
[-0.15,
0.44]     
Culture
broth
relative to
plasma
1.5 1.4 1.5  0.2 0.3 0.8
 [1.3, 1.7] [1.2,2.8]
[1.2,
1.7]     
(b)
ANTIMYCOBACTERIAL
IMMUNITY
      
Whole
blood
relative to
culture
broth
0.17 0.62 0.65  0.002 0.4 0.001
 [-0.10,0.43]
[0.43,
2.0]
[0.26,
1.0]     
Whole
blood
relative to
plasma
1.4 0.76 0.79  0.01 1.0 0.002
 [1.1, 1.4] [0.50,1.0]
[0.46,
1.2]     
*. Median [interquartile range] increase in luminescence measured in log10 relative
light units in each medium. Unpaired data comparisons were made with Wilcoxon
rank sum test and paired data comparisons were made with the Wilcoxon signed-
rank test.
doi: 10.1371/journal.pone.0074220.t002
0.76 logs (i.e. 6-times) more abundant than their negative-
control plasma.
There was no evidence of differences in antimycobacterial
immunity at high altitude between people who were usually
low-altitude residents versus long-term high-altitude residents
(Table 2b). This was true whether considering growth in whole
blood relative to positive-control culture broth (p=0.4) or
considering growth in whole blood relative to negative-control
plasma (p=1.0).
Age
Because of the difference in age between low and high-
altitude residents, we tested for an association between
participant age and the results of the antimycobacterial
immunity assay. Whether age was analyzed as a continuous
variable or a dichotomous variable (split by median age), and
whether analyzing all 77 assay results or only the 62 results for
assays performed at high altitude, there was no evidence of an
association between age and the antimycobacterial immunity
assay results (all p>0.4).
Quadruplet tubes in each assay
In contrast with the marked changes in mycobacterial growth
under different experimental conditions, there was minimal
variation in luminescence assessments of mycobacterial
concentrations between the identical quadruplicate tubes that
made up each assay (data not shown). Consequently,
repeating the above analyses using the average of the results
from the quadruplet identical tubes instead of the first tube did
not alter the study findings nor their statistical significance (see
supporting information Table S1).
Figure 2.  Restriction of mycobacterial growth by blood
relative to culture broth.  
doi: 10.1371/journal.pone.0074220.g002
Altitude Augments Human Antimycobacterial Immunity
PLOS ONE | www.plosone.org 5 September 2013 | Volume 8 | Issue 9 | e74220
Some of the results reported in this manuscript have been
previously reported in the form of an abstract [27].
Discussion
In this study we simplified an assay of human
antimycobacterial immunity to study altitude effects. This
demonstrated the feasibility of this assay for assessing
antimycobacterial immunity in low-resource settings and
revealed opposing effects of high altitude on the pathogen
versus the host. Specifically, ascent to high altitude both
facilitated the growth of the mycobacterial pathogen and
appeared to augment healthy participants’ immune resistance
to this pathogen. This antimycobacterial immunity was
assessed as the restriction of mycobacterial growth in whole
blood relative to positive-control culture broth and was also
inferred from the mycobacterial growth in whole blood relative
to negative-control acellular plasma.
High altitude settings have historically been associated with
apparent protection from TB [7] and people diagnosed with TB
still sometimes travel to high altitude because they believe that
this will cure their disease [28]. There is epidemiological
evidence from several countries that increasing altitude is
associated with decreased rates of TB latent infection [8,9] and
morbidity [12,14,15,29]. Even after adjusting these
epidemiological analyses for potentially confounding variables,
high altitude was associated with decreased rates of TB
disease [10,11,13,14] and death [16,17]. Several of these
studies were located in Peru, where the current research also
took place [8,9,15]. In the pre-antibiotic era these and other
factors led to patients with TB disease being treated with
ascent to and supportive care provided at high altitude, so-
called “altitude therapy” for TB [7]. Rigorous evaluation of this
approach appears to be lacking and it has largely fallen into
disuse since the advent of effective antimycobacterial
antibiotics.
The association between increasing altitude and reduced TB
might imply that high altitude directly impairs mycobacterial
growth. We found the opposite: that ascent to high altitude was
in fact associated with increased mycobacterial growth in both
culture broth and human plasma. Human antimycobacterial
immunity is largely cellular and consequently plasma would not
be expected to mount effective dynamic antimycobacterial
immune responses and plasma has long been known to be
tuberculostatic, neither supporting TB growth nor killing TB
[30]. The effect of altitude on extracellular mycobacterial growth
in plasma does not appear to have been defined previously,
and this part of our findings is consistent with studies of
aeration and oxygenation that, depending upon experimental
conditions, may stimulate or impair extracellular mycobacterial
growth [31-33]. Thus, high altitude stimulated extracellular
mycobacterial growth in human plasma under the experimental
conditions that we used.
In the current research, altitude-mediated augmentation of
extracellular mycobacterial growth in plasma was counteracted
by findings consistent with altitude-mediated augmentation of
cellular antimycobacterial immunity. This finding was apparent
for mycobacterial growth in whole blood compared with both
the positive-control culture-broth in each assay and also the
negative-control plasma from each individual. We have not
been able to identify previous human studies of altitude and
antimycobacterial immunity. However, our novel finding is
supported by experiments in: animals in which altitude
augmented antimycobacterial immunity [34]; in cells in which
hypoxia stimulated the human vitamin D-dependent
antimycobacterial pathway [32]; and in humans whose non-
specific cellular immunity was augmented by altitude [35,36].
These findings demonstrate increased immune resistance to
mycobacteria at altitude, which offers an explanation for the
apparent success of altitude therapy for TB. Other non-
immunological factors that may also contribute to reduced TB
transmission (and thus disease) at high altitude include
germicidal effects of altitude-associated ultraviolet light [37],
reduced humidity [38], and hypoxia [33].
Our objective to study the effect of altitude on human
antimycobacterial immunity was challenged by factors that we
addressed by developing a simplified assay of
antimycobacterial immunity. Firstly, the complexity of published
antimycobacterial immunity assays limited their feasibility in
high-altitude settings [19-22,24-26], so we simplified an assay
to require only portable equipment: hand-held incubator,
pipettes; and a briefcase sized luminometer. Secondly,
mycobacterial quantification is often inaccurate, technically
demanding and usually requires many weeks [19,20], so we
used genetically-modified luminescent mycobacteria
[21,22,24-26] and simplified their processing to quantify them
reliably and instantly, without centrifugation. Thirdly, large-
volume blood samples discourage participation; so we scaled
the assay to require less than 1.5 ml of blood. Fourthly, we
found in preliminary studies that day-to-day and place-to-place
variations in mycobacterial growth confounded assessments of
how well blood restricted mycobacterial growth, an issue that
was likely to worsen in the extreme environments involved in
our research. Consequently, we interpreted assays as relative
mycobacterial growth in blood compared with positive-control
culture-broth included in each assay and also relative to
concurrent negative-control plasma from each individual. We
used 1.5 ml of blood per participant but found high replicability
between quadruplicate assays, so recommend that in future
only single (not quadruplicate) assays be performed, which
would require only 0.3 ml (6 drops) of blood. This simplified,
low blood volume assay that uses only portable equipment
should facilitate assessment of human antimycobacterial
immunity in the resource-poor settings where most TB occurs
[6,25,26,39].
Limitations to this study include the lack of adjustment for
differences between the low and high altitude residents, such
as their age. However, we found no evidence of an association
between participant age and the results of the
antimycobacterial immunity assay. Furthermore, these
methodological limitations would not affect our experiment in
which antimycobacterial immunity was assessed in the same
individuals prior to and after ascent to high altitude. The
logistical challenges of transferring research participants and
the team and equipment for assessing antimycobacterial
immunity from low to high altitude restricted the number of
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participants in this part of the research. This small sample size
limits the certainty of our research findings that should be
replicated in a larger study. A potentially affordable strategy for
addressing this limitation in future research may be to re-assay
antimycobacterial immunity again in each participant after
returning to low altitude. It is also noteworthy that there is no
gold standard, validated in vitro correlate of antimycobacterial
immunity because no test has been shown to predict peoples’
resistance or susceptibility to TB infection or disease [25]. Thus
our finding that ascent to high altitude increased cellular
restriction of mycobacterial growth is consistent with but cannot
provide absolute confirmation for the long-reported altitude-
associated resistance to TB infection, disease and mortality.
The field use of this assay in a low-resource high-altitude
setting limited our capacity for: (1) mechanistic studies of cell
counts, cell types and immunological mediators and processes,
so future studies should store frozen aliquots of the assays to
characterize mediators of high altitude-augmentation of
antimycobacterial immunity and to determine whether altitude
directly augmented cellular anti-mycobacterial immunity or
whether indirect mechanisms such as altitude-mediated
changes in the mycobacterial and/or cellular nutrients or cell
counts in blood may have contributed [36]; (2) confirming that
luminescence predicted mycobacterial growth at high altitude
as it did in validation experiments at low altitude by ourselves
and by others [24] and that the altitude-associated effects on
mycobacterial luminescence indicated mycobacterial killing not
reduced metabolism or senescence; (3) using virulent M.
tuberculosis instead of low-virulence BCG mycobacteria that is
a relatively safe but imperfect surrogate for Mycobacterium
tuberculosis; and (4) studying the time course of altitude-
mediated augmentation of antimycobacterial immunity. It was
noteworthy that we found similar antimycobacterial immunity
less than one day after ascent to altitude as after long-term
residence there. Larger studies may differentiate the potentially
contributory mechanisms of altitude per se [36] versus
associated hypoxia [18], possible increased exposure to
sunlight increasing vitamin D levels [39] and nutritional
changes [26].
These findings do not imply that patients with difficult-to-treat
TB should migrate to high altitude, where we found that not
only the disease-resisting human immunity but also the
disease-causing pathogens were potentiated. However, our
findings provide some evidence for an altitude-mediated
augmentation of human antimycobacterial immunity that may
explain the anecdotal observation that TB patients often
improve and may even be cured when they move to high
altitude and the well-proven rarity of TB at high altitude. A so-
called “antibiotic apocalypse” of emerging resistance of
Mycobacterium tuberculosis to almost all known antibiotics
[40,41] has been reported. Thus, our findings justify rigorous
evaluation of how altitude affects antimycobacterial immunity
as this may be exploited to develop new treatments [6,32].
Clinical research is also needed to determine whether, as was
common practice in the pre-antibiotic era, the increasing
numbers of patients with TB resistant to all antibiotics would
benefit from their care being moved to high-altitude [40,41].
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